Canada - English - Health Canada

teva canada limited - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors

Canada - English - Health Canada

apotex inc - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors

Canada - English - Health Canada

angita pharma inc. - ticagrelor - tablet - 90mg - ticagrelor 90mg

Canada - English - Health Canada

taro pharmaceuticals inc - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate dihydrate maize starch mannitol opadry yellow 88a220017 purified talc purified water sodium stearyl fumarate starch - co-administered with acetylsalicylic acid (aspirin), this product is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) " in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). " in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

Israel - English - Ministry of Health

astrazeneca (israel) ltd - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1).limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.